Zeria Pharmaceutical

4559.TPhase 3

Tokyo, JapanFounded 1955zeria.co.jp

Zeria Pharmaceutical is a mid-sized, established Japanese pharmaceutical company with a history spanning over 70 years. It has built a stable business foundation through a multi-pronged strategy involving in-house development, strategic licensing, and marketing of both prescription and consumer health products. The company's strategic direction focuses on strengthening its core gastroenterology franchise while expanding into new therapeutic areas like dermatology and pursuing growth in Asian markets.

Market Cap

$178.1M

Founded

1955

Employees

1000-1500

Focus

Biotech

4559.T · Stock Price

USD 918.1827.27 (-2.88%)

Historical price data

AI Company Overview

Technology Platform

Zeria's core expertise lies in pharmaceutical development and formulation, particularly for gastrointestinal-targeted drug delivery, complemented by fermentation and processing technologies for functional foods through its subsidiary.

Pipeline Snapshot

25 drugs in pipeline, 11 in Phase 3

Drug	Indication	Stage
Z-100 + Placebo	Cervical Cancer	Phase 3
Z-213 + Saccharated Ferric Oxide	Iron Deficiency Anemia	Phase 3
Z-213	Iron Deficiency Anemia	Phase 3
Z-521	Primary Hypophosphatemic Rickets	Phase 3
Z-338 + Placebo	Functional Dyspepsia	Phase 3

Funding History

IPOUndisclosedUndisclosedMar 15, 2003

Opportunities

Growth opportunities include expanding the label and geographic reach of its core gastroenterology products, successfully launching its late-stage dermatology asset (Kikyou Extract) in China, and leveraging the growing consumer health and functional food markets in Asia.

Strategic in-licensing of late-stage clinical assets presents another avenue for pipeline expansion.

Risk Factors

Key risks include reliance on a few mature products facing future generic competition, clinical trial failures in its development pipeline, exposure to Japanese healthcare pricing reforms, and concentration of revenue in the domestic market.

Competitive Landscape

Zeria competes with global pharma giants (e.g., AbbVie, Takeda) in specialty gastroenterology and with large Japanese consumer healthcare companies (e.g., Daiichi Sankyo Healthcare) in the OTC space. Its differentiation is its integrated business model, strong domestic commercial footprint, and expertise in GI-focused drug development and formulation.

Publications

Patents

Pipeline